Skip to content
PsilodexMedication × psilocybin
Your list 00
Psychotropics
Brand names
Lybalvi
Reviewed 2026-09-30

Olanzapine–samidorphan

Clinical contraindication
Relative
Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence
Mechanism only
Half-life
35–52 h
Approximate, in adults. Detail in 01.
Named in state rules?
CONamed
ORNot named
NMPending
Cite asPsilodex: olanzapine-samidorphan · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Th

Olanzapine: strong 5-HT2A blockade blunts effects. Samidorphan blocks opioid analgesia.

Human data with psilocybin
None known: no published human data with psilocybin
Half-life
olanzapine 35–52 h; samidorphan 7–11 h (FDA label, checked 2026-09-30)
Evidence types on this record
ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

1 listed · counted on reports
Blocks 5-HT2A (may blunt effects)
Blocks the 5-HT2A receptor, the main receptor psilocybin acts through. Can reduce or block the psilocybin effect. Sources [1]

03 State rules

Official text governs
CO4 CCR 755-1
Named · 2.2(A)(6)–(7) · 2.5(A)(2)

Antipsychotic medications are named in rule, regardless of indication or dose. A Facilitator licensee may not provide services to a participant taking one without a referral for natural medicine services from a licensed provider, medical clearance from their medical or behavioral health provider, or a consultation and risk review with a medical or behavioral health provider. A Clinical Facilitator who does not prescribe antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider.

Colorado · checked 2026-09-30
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

  • Psychotic disorder or bipolar disorder (common indications)CO 2.2(A)(6)–(7) · CO 2.5(A)(2) · OR 333-333-5050(3)(j)

05 Sources

3
  1. Olanzapine–samidorphan — prescribing information · FDA label (DailyMed)
  2. Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
  3. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902. — class finding

Report an error in this record →

Before you startTerms v2026-10-01

What Psilodex is, and isn't.

  1. 01It describes published evidence and state rules. It is not medical advice, a screening decision, or clearance to participate.
  2. 02Starting, stopping, or changing a medication is the prescriber's decision. Bring the report to them.
  3. 03Your list stays in this browser. Nothing you enter is sent anywhere.

In an emergency, call 911. Full terms and privacy.